Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When
VG Oehler, IJ Huang, C Siu, M Kim, J Signorelli… - Journal of the National …, 2024 - jnccn.org
With the availability of BCR:: ABL1 targeted tyrosine kinase inhibitors (TKIs), outcomes for
most individuals with chronic phase chronic myeloid leukemia (CP-CML) are outstanding …
most individuals with chronic phase chronic myeloid leukemia (CP-CML) are outstanding …
Optical genome mapping as a Tool to unveil New Molecular findings in Hematological patients with Complex chromosomal rearrangements
N Coccaro, A Zagaria, L Anelli, F Tarantini, G Tota… - Genes, 2023 - mdpi.com
Standard cytogenetic techniques (chromosomal banding analysis—CBA, and fluorescence
in situ hybridization—FISH) show limits in characterizing complex chromosomal …
in situ hybridization—FISH) show limits in characterizing complex chromosomal …
Accelerated-phase CML: de novo and transformed
N Shanmuganathan, TP Hughes - Hematology, 2023 - ashpublications.org
Despite the dramatic improvements in outcomes for the majority of chronic myeloid leukemia
(CML) patients over the past 2 decades, a similar improvement has not been observed in the …
(CML) patients over the past 2 decades, a similar improvement has not been observed in the …
Diagnostic Ambiguity Caused by an Atypical e18a2 BCR::ABL1 Transcript in a Chronic Myeloid Leukemia Patient
T Pretzsch, S Progscha… - Case Reports in …, 2024 - Wiley Online Library
We describe the case of a chronic myeloid leukemia (CML) patient with a rare atypical
e18a2 BCR:: ABL1 transcript. The generation of this transcript was explained by a detailed …
e18a2 BCR:: ABL1 transcript. The generation of this transcript was explained by a detailed …
[HTML][HTML] New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use
CA Schiffer - Haematologica, 2023 - ncbi.nlm.nih.gov
The impact of tyrosine kinase inhibitors (TKI) on the treatment of chronic myeloid leukemia
(CML) has been extraordinary, with overall survival of patients treated in chronic phase now …
(CML) has been extraordinary, with overall survival of patients treated in chronic phase now …
Beyond BCR:: ABL1—The Role of Genomic Analyses in the Management of CML
S Branford, A Fernandes, NH Shahrin… - Journal of the National …, 2024 - jnccn.org
Chronic myeloid leukemia (CML) is a model of genomically based diagnosis and
management where BCR:: ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) …
management where BCR:: ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) …